Edaravone (Radical Scavenger) versus sodium ozagrel (Antiplatelet Agent) in acute noncardioembolic ischemic stroke (EDO Trial)

Cerebrovascular Diseases

Volumn 27, Issue 5, 2009, Pages 485-492

  Shinohara, Yukito ^a   Saito, Isamu ^b   Kobayashi, Shotai ^c   Uchiyama, Shinichiro ^d  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b Fuji Brain Institute and Hospital   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiplatelet agent; Edaravone; Ozagrel; Radical scavenger; Stroke at acute stage; Stroke prevention

Indexed keywords

ANTITHROMBOCYTIC AGENT; NORPHENAZONE; OZAGREL; SCAVENGER;

AGED; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; FEMALE; HUMAN; ILEUS; KIDNEY DISEASE; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SUICIDE;

AGED; AGED, 80 AND OVER; ANTIPYRINE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; JAPAN; MALE; METHACRYLATES; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STROKE; TREATMENT OUTCOME;

EID: 62849084592     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210190     Document Type: Article

References (25)

1. Edaravone Acute Brain Infarction Study Group: Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Cerebrovasc Dis 2003; 15:222-229.
2. Joint Committee on Guidelines for the Management of Stroke:: Japanese Guidelines for the Management of Stroke 2004 (in Japanese). Tokyo, Kyowa Kikaku, 2004.
3. Shinohara Y, Yamaguchi T: Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke 2008;3:55-62.
4. Otomo E, Kutsuzawa T, Kogure K, Hirai S, Goto F, Terashi A, Tazaki Y, Araki G, Ito E, Fujishima M, Nakashima M: Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis: double-blind trial in comparison with placebo (in Japanese with English abstract). J Clin Therapeut Med 1991;7:353-388.
5. Kobayashi S, Tazaki Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23:531-534.
6. Ohta T, Kikuchi H, Hashi K, Kudo Y: Nizofe-none administration in the acute stage following subarachnoid hemorrhage: results of a multi-center controlled double-blind clinical study. J Neurosurg 1986;64:420-426.
7. Van Swieten JC, Koudstaal PJ, Visser MC, Shouten HJA, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604-607.
8. Shinohara Y, Minematsu K, Amano T, Ohashi Y: Modified Rankin scale with expanded guidance scheme and interview questionnaire: interrater agreement and reproducibility of assessment. Cerebrovasc Dis 2006;21:271-278.
9. Mahoney FI, Barthel DW: Functional evaluation: Barthel Index. Md Med J 1965; 14:61-65.
10. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
11. http://www.jsts.gr.jp/guideline/222-222.pdf (in Japanese, accessed November 2008).
12. Japan Stroke Scale Committee: Japan Stroke Scale (Motor Function) (in Japanese). Jpn J Stroke 1999;21:353-356.
13. Fukuuchi Y, Tohgi H, Shinohara Y, Kobayashi S, Fujishima M, Tazaki Y, Ogawa N, Kan S: A controlled clinical trial to assess the efficacy and safety of argatroban in treating acute cerebral thrombosis in comparison to sodium ozagrel (in Japanese with English abstract). Neurol Ther 2001;18:273-282.
14. Koch GG, Tangen CM: Nonparametric analysis of covariance and its role in noninferiority clinical trials. Drug Inf J 1999;33:1145-1159.
15. European Agency for the Evaluation of Medicinal Products: Concept paper on the development of a Committee for Proprietary Medicinal Products (CPMP): points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. London, CPMP, 1999.
16. Watanabe T, Morita I, Nishi H, Murota S: Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81-87.
17. Watanabe T, Yuki S, Egawa M, Nishi H: Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:1597-1604.
18. Abe K, Yuki S, Kogure K: Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19:480-485.
19. Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A: Effect of MCI-186 on brain edema in rats. Stroke 1989;20:1236-1240.
20. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito K: Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997;281:921-927.
21. Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K, Kogure K: Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997;762:240-242.
22. Mizuno A, Umemura K, Nakashima M: Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998;30:575-578.
23. Shibata H, Arai S, Izawa M, Murasaki M, Takamatsu Y, Izawa O, Takahashi C, Tanaka M: Phase I clinical study of MCI-186 (edaravone, 3-methyl-l-phenyl-2- pyrazolin-5-one) in healthy volunteers: safety and pharmaco-kinetics of single and multiple administrations (in Japanese with English abstract). Jpn J Clin Pharmacol Ther 1998;29:863-876.
24. Naito J, Komatsu H, Ujiie A, Hamano S, Kubota T, Tsuboshima M: Effects of throm-boxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol 1983;91: 41-48.
25. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.